Intech Investment Management LLC Has $962,000 Holdings in GeneDx Holdings Corp. $WGS

Intech Investment Management LLC cut its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 41.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,929 shares of the company’s stock after selling 6,200 shares during the period. Intech Investment Management LLC’s holdings in GeneDx were worth $962,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada lifted its position in shares of GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after buying an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after acquiring an additional 453 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of GeneDx by 270,700.0% in the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after acquiring an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of GeneDx by 67.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after acquiring an additional 11,375 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in GeneDx by 63.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 14,942 shares of the company’s stock worth $1,379,000 after purchasing an additional 5,823 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated/institutional buy: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, a strong signal of institutional confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director buying: Director Keith A. Meister made two recent purchases (140,026 shares on Mar 5 at ~$81.19 and 29,495 shares on Mar 3 at ~$70.89), increasing his stake to over 3.2M shares — a large insider accumulation that typically signals confidence and can drive demand. SEC ownership filing — Keith A. Meister purchases
• Positive Sentiment: Recent earnings beat: GeneDx topped consensus on its most recent quarterly EPS and delivered revenue roughly in line with estimates, supporting a bullish narrative around recurring revenue and margin progress (analyst consensus remains a Moderate Buy with elevated price targets).
• Neutral Sentiment: Short-interest reading shows 0 reported short interest as of Mar 5, which appears to be a data anomaly and offers little actionable signal on immediate directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 (~$2.0M) and cut her direct stake materially. Significant insider sales can worry some investors about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 (~$486k), trimming his position by roughly 25%; this adds to mixed insider signals even though the size is smaller than the institutional buys. SEC Form 4 — CFO sale

GeneDx Stock Up 7.5%

WGS opened at $88.11 on Monday. The business has a 50 day moving average of $100.80 and a 200-day moving average of $122.19. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of -117.48 and a beta of 2.03. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. As a group, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Activity at GeneDx

In related news, COO Bryan Dechairo sold 5,961 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total value of $510,857.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 6,187 shares of GeneDx stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total value of $486,360.07. Following the sale, the chief financial officer directly owned 18,674 shares in the company, valued at approximately $1,467,963.14. This trade represents a 24.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 62,607 shares of company stock valued at $6,421,523. Company insiders own 29.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on WGS. BTIG Research decreased their target price on GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a research report on Tuesday, February 24th. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research note on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Zacks Research upgraded shares of GeneDx from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of GeneDx from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $150.71.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.